Since previous studies on Jurkat T cells or breast cancer cells demonstrated an upregulation of TRAIL receptor R2/DR5 after combined treatment with TRAIL and irradiation [54,31] two different application schedules were tested. This evidence concerns the gene TNFSF10 and breast carcinoma.